Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KN026 + docetaxel
- Development stage
- Unknown
- Lead developer
- AlphaMab Oncology
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
KN026 + docetaxel is a combination therapy consisting of KN026, a recombinant humanized bispecific antibody targeting the HER2 protein at domains II and IV (the binding sites for pertuzumab and trastuzumab), and docetaxel, a taxoid antineoplastic agent. This combination is being investigated as a first-line treatment for HER2-positive recurrent or metastatic breast cancer. KN026 blocks HER2 signaling by dual engagement of two distinct epitopes on the receptor, potentially overcoming resistance to standard anti-HER2 therapies. Docetaxel disrupts microtubule function during cell division, leading to apoptosis in rapidly dividing tumor cells. Clinical trials have demonstrated that this regimen achieves high objective response rates with manageable safety profiles in patients with HER2-positive metastatic breast cancer[1][3][5].
- Other names
- anbenitamab + docetaxelKN026 + chemotherapyKN026 + docetaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on KN026 + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KN026 + docetaxel.